Supernus Pharmaceuticals (SUPN) Intangibles (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Intangibles data on file, last reported at $549.7 million in Q1 2026.

• On a quarterly basis, Intangibles rose 9.48% year-over-year to $549.7 million in Q1 2026; TTM through Mar 2026 was $549.7 million, a 9.48% increase from a year earlier, with the FY2025 full-year figure at $569.5 million, up 9.11% from the prior year.
• Intangibles for Q1 2026 stood at $549.7 million, down from $569.5 million in the prior quarter.
• Over the last five years, Intangibles for SUPN reached as high as $764.0 million in Q1 2022 and fell as low as $481.3 million in Q2 2025.
• Historically, Intangibles has averaged $614.5 million across 5 years, with a median of $599.9 million in 2023.
• Across the five-year window, Intangibles surged 112.98% in 2022 and declined 15.75% in 2024, its largest moves.
• Year by year, Intangibles stood at $702.5 million in 2022, then decreased by 14.6% to $599.9 million in 2023, then decreased by 13.0% to $521.9 million in 2024, then grew by 9.11% to $569.5 million in 2025, then dropped by 3.47% to $549.7 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $549.7 million in Q1 2026, $569.5 million in Q4 2025, and $623.5 million in Q3 2025.